Evaluation of insulin-like growth factor-1 and parathyroid hormone on growth characteristics of MG-63 cells.
Insulin-like Growth Factor-1 (IGF-1) and Parathyroid hormones (PTH) are major endocrine secretions that contribute to bone formation. The purpose of this experiment was to examine MG-63 bone like cells after treatment with PTH and IGF-1 in low (1 ug), medium (5 ug), and high (50 ug) dosage levels. MG-63 cells were plated onto a 24 well tissue culture plate at a density of 1 x 1--5 cells per well. The experiment was designed to evaluate cell counts, cell damage (MDA), protein levels, calcium levels, alkaline phosphatase levels, and cellular morphology after 24, 48, and 72 hours post incubation with IGF-1 and PTH. Both hormones stimulated cellular mitotic division as evidenced by morphology and cell numbers. There was an inverse relationship between dose and cell number with the lower dose of IGF-1 and PTH causing the most increase. In both hormones, the exposure to the highest dose induced the largest MDA level increase. However, in the protein levels, few changes in protein levels were found with IGF-1, but PTH showed an increase of protein levels over the time periods. Morphological evaluation showed prominent nucleoli and cellular division throughout both treatments, however the cells with IGF-1 became extremely elongated and the cells with PTH became rather plump. The information gathered suggests that IGF-1 and PTH have an anabolic effect on MG-63 and the effect is dose dependent with both treatments with the lower dose being more effective.
Franklin
Laura
L
University of Mississippi Medical Center, Jackson, MS 39216, USA.
Haynie
Lisa
L
Davis
Joel
J
Tucci
Michelle
M
Benghuzzi
Hamed
H
Russell
George
G
Ragab
Ashraf
A
D002454:Cell Differentiation / Q000187:drug effects; D002460:Cell Line; D049109:Cell Proliferation / Q000187:drug effects; D048429:Cell Size / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000008:administration & dosage*; D010006:Osteoblasts / Q000166:cytology* / Q000187:drug effects / Q000502:physiology*; D010281:Parathyroid Hormone / Q000008:administration & dosage*
D004338:Drug Combinations; D010281:Parathyroid Hormone; D007334:Insulin-Like Growth Factor I